Bilateral Sequential Photodynamic Therapy for Sub-retinal Neovascularization With Type 2A Parafoveal Telangiectasis - 18/08/11
, Taraprasad Das, MD : FRCS, Kallukuri Sumasri, BS Opt, L.S. Mohan Ram, Oph Tech
Address reprint requests to Nazimul Hussain, MS, DNB, Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Eye Institute, L.V. Prasad Marg, Banjara Hills, Hyderabad-500 034, Andhra Pradesh, India; fax: (+91) 40-23548271Résumé |
Purpose |
To report the results of repeated bilateral sequential photodynamic therapy (PDT) with verteporfin for sub-retinal neovascularization associated with parafoveal telengiectasia.
Design |
Interventional case series.
Methods |
Three patients (minimum of 6-month follow-up) were analyzed after bilateral sequential PDT for parafoveal telengiectasia-associated sub-retinal neovascularization.
Results |
Mean age was 53.3 ± 2.1 years. Mean and median follow-up duration were 12.3 and 10 months, respectively. Mean initial Early Treatment of Diabetic Retinopathy Study chart letter acuity was 30.6 in right eyes and 19 in left eyes, and at month 6, it was 30.6 in right eyes and 22.3 in left eyes. All patients received bilateral treatment three times; one eye received a fourth treatment. The greatest linear diameter was between 2310 and 5400 μm.
Conclusion |
PDT is a viable treatment for sub-retinal neovascularization associated with parafoveal telengiectasia. Bilateral sequential treatment is a convenient way to treat bilateral disease.
Le texte complet de cet article est disponible en PDF.
Vol 140 - N° 2
P. 333-335 - août 2005 Retour au numéro
Article précédent
- Surgical Management of Traumatic Macular Hole–Related Retinal Detachment
- Yen-Po Chen, Tun-Lu Chen, An-Ning Chao, Wei-Chi Wu, Chi-Chun Lai
- B-Cells in Ocular Adnexal Lymphoproliferative Lesions Express B-cell attracting Chemokine 1 (CXCL13)
- Katherine M. Falkenhagen, Rita M. Braziel, Frederick W. Fraunfelder, Justine R. Smith
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?